Table 1.
Study Design
| Race/Ethnicity | Sex | Lesion Body Region | Nonlesional Body Region | Baseline Biopsies | Rebiopsies/Follow-Up Visits | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| African American | F | Abdomen | Ctrl | ||||||||
| African American | F | Back | Ctrl | NonLes_b | Nonlesional baseline biopsy (n = 8) | ||||||
| Asian | M | Arm | Ctrl | NonLes_r | Nonlesional rebiopsy (n = 5) | ||||||
| White | F | Back | Ctrl | KEar | Keloid ear biopsy (n = 9) | ||||||
| White (n = 2) | F | Abdomen | Ctrl | KE_b | Keloid edge baseline biopsy (n = 25) | ||||||
| African American | F | Abdominoplasty | AbPlast | KE_r | Keloid edge rebiopsy (n = 13) | ||||||
| Hispanic/Latino (n = 2) | F | Abdominoplasty | AbPlast | Ctrl | Control (n = 6) | ||||||
| Unknown | F | Abdominoplasty | AbPlast | AbPlast | Abdominoplasty (n = 10) | ||||||
| White (n = 6) | F | Abdominoplasty | AbPlast | ||||||||
| AfricanAmerican (n = 3) | F | Ear | KEar | ||||||||
| Asian | F | Ear | KEar | ||||||||
| Hispanic/Latino | M | Ear | KEar | ||||||||
| White | F | Ear | KEar | ||||||||
| Asian (n = 2) | F | Back/ear | KE_b | KEar | |||||||
| African American | F | Arm | KE_b | ||||||||
| African American | F | Back | KE_b | ||||||||
| Asian | M | Arm | KE_b | ||||||||
| Hispanic/Latino | M | Back | KE_b | ||||||||
| NativeHawaiian/PacificIslander | F | Arm | KE_b | ||||||||
| White | M | Chest | KE_b | ||||||||
| White | M | Back | KE_b | ||||||||
| African American | M | Arm | Arm | KE_b | NonLes_b | ||||||
| African American | F | Back | Back | KE_b | NonLes_b | ||||||
| African American | M | Chest | Chest | KE_b | NonLes_b | ||||||
| African American | M | Chest | KE_b | 47d | KE_r | ||||||
| African American | M | Arm | KE_b | 49d | KE_r | ||||||
| White | F | Arm | KE_b | 52d | KE_r | ||||||
| White | F | Chest | KE_b | 56d | KE_r | ||||||
| Asian | M | Arm | KE_b | 61d | KE_r | ||||||
| African American | F | Back | KE_b | 71d | KE_r | ||||||
| Asian | M | Chest | KE_b | 93d | KE_r | ||||||
| African American | M | Chest | KE_b | 97d | KE_r | ||||||
| AfricanAmerican | M | Chest | Arm | KE_b | NonLes_b | 62d | KE_r | NonLes_r | |||
| AfricanAmerican | M | Back | Back | KE_b | NonLes_b | 90d | KE_r | NonLes_r | |||
| AfricanAmerican | F | Chest | Chest | KE_b | NonLes_b | 90d | KE_r | NonLes_r | |||
| AfricanAmerican | F | Chest | Chest | KE_b | NonLes_b | 98d | KE_r | NonLes_r | |||
| African American | F | Abdomen | Abdomen | KE_b | NonLes_b | 69d | KEar | 107d | KE_r | NonLes_r | |
Abbreviations: Ctrl, control; F, female; M, male.
The table shows the study participants and the biopsies collected. The number of subjects with identical information is indicated inside red parenthesis. Baseline lesions, taken from the periphery without adjacent normal skin and untreated for a minimum of 6 months, were obtained from the ear (KEar) or torso (KE_b) (broadly categorized into arm, chest, abdomen, and back). Biopsy locations were determined by subject choice. Nonlesional biopsies (NonLes_b) were obtained from within 5 cm of lesional biopsy (generally within ∼2–3 cm). Rebiopsies (KE_r and NonLes_r) were taken from the same location as baseline biopsies, with days from baseline biopsy indicated in gray. Two Ctrl groups consisted of healthy volunteers (Ctrl) and abdominoplasty discard skin (AbPlast). Intralesional triamcinolone injections were given if the subject developed keloid at the site of nonlesional biopsy.